交流合作

您所在位置:首页 > 交流合作 > 正文

药企的研发“套路”:我们应该怎样创新

文章作者:www.cs-vaccine.com发布时间:2020-03-31浏览次数:905

R&D strength is the heart of pharmaceutical enterprises. But R&D is facing many challenges, such as low success rate of R&D within enterprises, rising R&D cost, long R&D cycle and expiration of fist products. These pressures make participants in new drug research and development constantly seek mode innovation to support industrial development.

Figure 1 Pharmaceutical Enterprise R&D Input 2016

Data Source: The European Commission released the "Global R&D Input List 2016". The survey counted R& D expenditure of 2 500 enterprises in the world in fiscal year 2015/16.

Place an order with a data company

Many analysts believe that having reliable and well-correlated data is one of the biggest challenges facing pharmaceutical R&D. Recently, Palantir, a data company that helped U.S. intelligence agencies find bin Laden, received a special order. The order came from the pharmaceutical industry, and Merck Germany asked it to use data collected from service analysis experiments to help them shorten the time needed to develop new drugs. In addition, Merck will use Palantir's software to solve specific problems in the supply chain, such as drug demand forecasting. Despite the challenges ahead, the opportunities for big data in pharmaceutical R&D are real and the rewards are expected.

Small Teams of Large Companies

In order to achieve the "security" of R&D and the effective utilization of external resources, some large pharmaceutical companies will set up subsidiaries that can independently manage and independently select R&D partners. Colus, founded by Lilai in 2002, is a good example. Chorus is relatively independent, and all new drug development is based on the combination of virtual R&D and outsourcing services, mainly relying on outsourcing services to complete the design, chemical synthesis, production process, quality control, to clinical.

毒理学,生物学和早期临床试验。这种虚拟化模式开发了“快速,快速失败”的新药开发概念,以更少的资源,最快和最全面的方式评估更多的新药开发项目,并成为礼来公司产品线的重要来源。

通过平台“借力”

建立核心技术平台也是制药公司促进研究和开发的常用“惯例”之一。

该平台通过技术许可实施。例如,去年8月,吉利德与丹麦Genmab签署了双特异性抗体技术许可协议。根据协议,吉利德已获得使用Genmab双特异性平台开发艾滋病治疗的独家许可,Genmab也将增加新的收入来源。国内的例子并不少见。去年12月,佩奇生物医药(苏州)有限公司与辉瑞公司签署协议,进一步研究和开发糖尿病激素药(GKA)在糖尿病的最前沿。辉瑞将从事研发,临床前数据和支持是在专有技术方面提供的。这种“接力”对行业持乐观态度。

该平台也可以通过投资或收购来实现。据了解,大型制药公司的风险投资基金平均约2.5亿美元,而年投资额约为20万美元。风险投资基金可以同时投资于初创公司,小型生物技术公司和虚拟制药公司,这些公司随着商业模式的不断调整而出现。

图2 2016年获得A轮融资的制药公司示例

资料来源:战略交易